Early phase clinical trials-are dose expansion cohorts needed?

被引：23
|
作者：
Iasonos, Alexia [1 ]
O'Quigley, John [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[2] Univ Paris 06, F-75005 Paris, France
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2015年 / 12卷 / 11期
关键词：
I TRIALS; DESIGN; CANCER; SAFETY;
D O I：
10.1038/nrclinonc.2015.174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Dose-expansion cohorts (DECs) enable investigators to identify potentially effective drugs, for specific patient populations, in a single trial by assessing antitumour activity as early as possible. We discuss how the objectives, design and interpretation of DEC have evolved, and how DECs are changing the landscape of early drug development.
引用
收藏
页码：626 / 628
页数：2
相关论文
共 50 条
  • [1] Early phase clinical trials—are dose expansion cohorts needed?
    Alexia Iasonos
    John O'Quigley
    Nature Reviews Clinical Oncology, 2015, 12 : 626 - 628
  • [2] Stopping rules for phase I clinical trials with dose expansion cohorts
    Devlin, Sean M.
    Iasonos, Alexia
    O'Quigley, John
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2022, 31 (02) : 334 - 347
  • [3] A Statistical Evaluation of Dose Expansion Cohorts in Phase I Clinical Trials
    Boonstra, Philip S.
    Shen, Jincheng
    Taylor, Jeremy M. G.
    Braun, Thomas M.
    Griffith, Kent A.
    Daignault, Stephanie
    Kalemkerian, Gregory P.
    Lawrence, Theodore S.
    Schipper, Matthew J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (03):
  • [4] Dose Expansion Cohorts in Phase I Trials
    Iasonos, Alexia
    O'Quigley, John
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (02): : 161 - 170
  • [5] Design Considerations for Dose-Expansion Cohorts in Phase I Trials
    Iasonos, Alexia
    O'Quigley, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) : 4014 - +
  • [6] Adaptive dose insertion in early phase clinical trials
    Hu, Bo
    Bekele, B. Nebiyou
    Ji, Yuan
    CLINICAL TRIALS, 2013, 10 (02) : 216 - 224
  • [7] Sequential monitoring of Phase I dose expansion cohorts
    Iasonos, Alexia
    O'Quigley, John
    STATISTICS IN MEDICINE, 2017, 36 (02) : 204 - 214
  • [8] EVOLUTION OF CLINICAL TRIAL DESIGN IN EARLY DRUG DEVELOPMENT: THE USE OF EXPANSION COHORTS (ECS) IN PHASE I CANCER TRIALS (PITS)
    Manji, A.
    Garcia, I. Brana
    Amir, E.
    Tannock, I. F.
    Bedard, P.
    Oza, A. M.
    Siu, L.
    Razak, A. R. A.
    ANNALS OF ONCOLOGY, 2012, 23 : 158 - 158
  • [9] Continuous safety monitoring in large phase I cancer clinical trials with multiple expansion cohorts
    Kocherginsky, Masha
    Karrison, Theodore
    TRIALS, 2017, 18
  • [10] Combined criteria for dose optimisation in early phase clinical trials
    Alam, M. Iftakhar
    Coad, D. Stephen
    Bogacka, Barbara
    STATISTICS IN MEDICINE, 2019, 38 (21) : 4172 - 4188
12345